Tasimelteon - CAS 609799-22-6
Catalog number: B0084-072984
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Certificate of Analysis-Tasimelteon 609799-22-6 B16TSMT0425  
Melatonin Receptor
Tasimelteon (trade name Hetlioz) is a drug approved by the FDA solely for the treatment of non-24-hour sleep–wake disorder (often designated as N24HSWD) in totally blind adults. It is a selective agonist for the melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, similar to other members of the melatonin receptor agonist class of which ramelteon (2005) and agomelatine (2009) were the first approved.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-072984 100 mg $498 In stock
B0084-072984 1 g $899 In stock
Bulk Inquiry
Brife Description:
Tasimelteon is a novel circadian regulator, is the first product for the treatment of Non-24-hour Sleep-Wake Disorder (Non-24) approved by either the FDA or the European Medicines Agency (EMA).It is also a melatonin MT1 and MT2 receptor agonist.
≥ 99.0%
White to off-white Solid
BMS-214,778; BMS-214778; BMS214778; BMS 214778. VEC-162; VEC162; VEC 162. Trade name: Hetlioz.
Chloroform, Methanol
Tasimelteon is a novel drug, used in the treatment of non-24 hour sleep-wake disorder. It helps to correct the circadian rhythm disorder often seen in patients who are visually impaired.
Quality Standard:
In-house Standard
Boiling Point:
442.6±24.0 °C | Condition: Press: 760 Torr
Melting Point:
57 - 65°C
1.145 g/cm3
Canonical SMILES:
1.Jet Lag and Psychotic Disorders
Gregory Katz. Curr Psychiatry Rep (2011) 13:187–192
Newly developed melatonin agonist tasimelteon (VEC-162) has been evaluated recently in phase 2 and phase 3 randomized, double-blind, placebo-controlled, parallelgroup studies for treatment of transient insomnia after sleep–time shift. Results were encouraging, and although they were not yet specifically applied to jet lag symptoms, they showed that after an abrupt advance in sleep time, tasimelteon improved sleep initiation and maintenance concurrently with a shift in endogenous circadian rhythms.
2.Circadian-Based Therapies for Circadian Rhythm Sleep-Wake Disorders
Helen J. Burgess & Jonathan S. Emens. Curr Sleep Medicine Rep
There were two new publications concerning blind individuals with N24SWD. Most important was Lockley et al.’s study of the drug tasimelteon in this population which became the first medication approved by the FDA for the treatment of any CRSWD. The study was a randomized, placebo controlled study in 84 individuals with N24SWD comparing 20 mg of tasimelteon and placebo administered 1 h before a target bedtime. Tasimelteon was found to safely and effectively treat individuals with N24SWD: entrainment (synchronization to the 24-h day) occurred in 20 % (8 of 40) of patients receiving the drug compared with 3 % (1 of 38) receiving placebo. As noted in the AASM CRSWD practice guideline, the entrainment rate was lower than the 67 % entrainment rate (12 of 18 patients) found in the metaanalysis of melatonin treatment in N24SWD. However, as noted by the authors themselves, this may have been because entrainment was assessed after just 1 month of treatment. Such a theory is borne out by the higher rates of entrainment found during the longer, open label treatment with tasimelteon. The tasimelteon study also demonstrated improvements (increases and decreases, respectively) in nighttime and daytime sleep (as measured by the worst quartiles of treatment days compared to baseline). Of note, the tasimelteon study could also be considered to include a component of prescribed sleep/wake scheduling as subjects were instructed to maintain selfselected 9-h sleep opportunities with bedtimes within a 4-h range (21:00 to 01:00). The second new publication in N24SWD was a small placebo controlled study by St. Hilaire and Lockley looking at the effects of caffeine on entrainment in three blind individuals with the disorder. Caffeine (150 mg at 10 am) failed to entrain the subjects although it did improve daytime alertness in the setting of circadian misalignment.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Melatonin Receptor Products

CAS 196597-26-9 Ramelteon

(CAS: 196597-26-9)

Ramelteon has high affinity with recombinant human MT1 and MT2 receptors with pKi of 10.05 and 9.70, respectively.

CAS 343263-95-6 DH 97

DH 97
(CAS: 343263-95-6)

DH 97 is a selective MEL-1B-R (melatonin receptor) antagonist.

CAS 220339-00-4 DH 97

DH 97
(CAS: 220339-00-4)

DH 97 is a potent MT2 melatonin receptor antagonist (pKi = 8.03) with 89- and 229-fold selectivity over MT1 and GPR50 (melatonin-related orphan receptor) respec...

CAS 93515-00-5 2-Iodomelatonin

(CAS: 93515-00-5)

2-Iodomelatonin is a potent agonist of the melatonin receptors 1 (MT1) with Ki value of 28 pM. It could be used to identify, characterize and localize melatonin...

CAS 609799-22-6 Tasimelteon

(CAS: 609799-22-6)

Tasimelteon (trade name Hetlioz) is a drug approved by the FDA solely for the treatment of non-24-hour sleep–wake disorder (often designated as N24HSWD) in tota...

LY 156735
(CAS: 118702-11-7)

This active molecular is high affinity nonselective melatonin receptors MT1 and MT2 agonist which is under development for the treatment of insomnia and other s...

CAS 117946-91-5 Luzindole

(CAS: 117946-91-5)

Luzindole is a melatonin receptor antagonist which preferentially targets MT1B.

CAS 63762-74-3 6-Chloromelatonin

(CAS: 63762-74-3)

6-Chloromelatonin is a potent agonist of the melatonin receptors, which is active at nanomolar concentrations. It shows higher affinity for binding to hamster b...

Chemical Structure

CAS 609799-22-6 Tasimelteon

Quick Inquiry

Verification code

Featured Items